Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation

The World Health Organization recommends Xpert for initial diagnosis in individuals suspected of having multidrug-resistant TB (MDR- TB) or HIV-associated TB, and many countries are moving quickly toward adopting Xpert. As roll-out proceeds, it is essential to understand the potential health impact and cost-effectiveness of diagnostic strategies based on Xpert. This paper evaluates potential health and economic consequences of implementing Xpert in five southern African countries-Botswana, Lesotho, Namibia, South Africa, and Swaziland-where drug resistance and TB-HIV coinfection are prevalent.

Document Date: 20 November, 2012
Author: Nicolas A. Menzies and others